PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer

Phase 1/2 Unknown 29 enrolled Wakayama Medical University Human Genome Center, Institute of Medical Science, University of Tokyo · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single institution phase I / II trial to evaluate the safety and efficacy of URLC10-177 and TTK-567 emulsified with Montanide ISA 51 in combination with different doses of CpG7909 in patients with advanced or recurrent esophageal cancer.

Timeline

Start: 2006-11
Primary completion: 2009-11
Completion: —

Publications

Iwahashi M, Katsuda M, Nakamori M, Nakamura M, Naka T, Ojima T, Iida T, Yamaue H. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci. 2010 Dec;101(12):2510-7. doi: 10.1111/j.1349-7006.2010.01732.x. Epub 2010 Sep 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TTK-567	Peptide	1 mg	Subcutaneous
Subject	URLC10-177	Unknown	1 mg	Subcutaneous
Subject	agatolimod	Oligonucleotide (other)	0 mg/kg	Subcutaneous
Subject	agatolimod	Oligonucleotide (other)	0.02 mg/kg	Subcutaneous
Subject	agatolimod	Oligonucleotide (other)	0.1 mg/kg	Subcutaneous

PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer

Summary

Timeline

Publications

Drugs

Indications